UBS Group
CNTX icon

UBS Group’s Context Therapeutics CNTX Stock Holding History

UBS Group’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Buy
28,183
+21,995
+355% +$44.6K ﹤0.01% 8308
2026
Q1 		$16.2K Buy
6,188
+5,698
+1,163% +$13.3K ﹤0.01% 8081
2025
Q4 		$720 Sell
490
-6,892
-93% -$8.05K ﹤0.01% 9835
2025
Q3 		$7.15K Buy
7,382
+7,012
+1,895% +$5.68K ﹤0.01% 8742
2025
Q2 		$242 Sell
370
-62
-14% -$45 ﹤0.01% 9905
2025
Q1 		$264 Sell
432
-698,697
-100% -$608K ﹤0.01% 9861
2024
Q4 		$734K Buy
699,129
+697,412
+40,618% +$1.21M ﹤0.01% 5560
2024
Q3 		$3.37K Buy
+1,717
New +$3.81K ﹤0.01% 8276
2024
Q1 		– Sell
-9,490
Closed -$10.7K – 9395
2023
Q4 		$10.7K Buy
+9,490
New +$10.2K ﹤0.01% 7425
2023
Q2 		– Sell
-5,767
Closed -$3.24K – 9005
2023
Q1 		$3.24K Buy
5,767
+3,012
+109% +$2.28K ﹤0.01% 8352
2022
Q4 		$1.79K Buy
+2,755
New +$2.97K ﹤0.01% 9790
2022
Q3 		– Sell
-3,627
Closed -$8K – 10404
2022
Q2 		$8K Buy
+3,627
New +$6.8K ﹤0.01% 8291

Other funds holding CNTX

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group's CNTX Position: Q2 2026 in Review

UBS Group increased its Context Therapeutics (CNTX) stake by 355% in Q2 2026, buying an estimated $44.6K and bringing the position to 28,183 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #8308.

UBS Group first reported a position in CNTX in Q2 2022 and has held it in 12 quarters since. The position peaked at $734K in Q4 2024. 43 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • UBS Group held 28,183 shares of Context Therapeutics worth $15.6K as of Q2 2026.
  • UBS Group bought 21,995 Context Therapeutics shares in Q2 2026, an estimated $44.6K.
  • Context Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8308 holding.
  • UBS Group first reported a position in Context Therapeutics in Q2 2022 and has held it in 12 quarters since.
  • UBS Group's Context Therapeutics position peaked at $734K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.